Cited by 515Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsCardiac tumors and thrombi

Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Open access
Strauss, S.J., Frezza, A.M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y. +73 more·2021·Annals of Oncology

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2021.08.1995

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Osteosarcoma is regarded as a radio-resistant disease.

    “Although osteosarcoma is regarded as a radio-resistant disease, radiotherapy as local control may be considered if resection of a primary tumour is not possible or anticipated to lead to unacceptable morbidities such as in pelvic, trunk or craniofacial primary sites of disease 104 .”

    From Osteosarcoma (2022) · cites this paper as [104]

  • The recommended recurrence regimens include high-dose ifosfamide with or without etoposide and gemcitabine and docetaxel.

    “The regimens include high-dose ifosfamide with or without etoposide and gemcitabine and docetaxel.”

    From Osteosarcoma (2022) · cites this paper as [104]

  • Several chemotherapy regimens are recommended by NCCN and ESMO guidelines at the time of osteosarcoma recurrence.

    “Several chemotherapy regimens are recommended by the National Cancer Care Network (NCCN) and European Society of Medical Oncology (ESMO) guidelines at the time of osteosarcoma recurrence 104,141 .”

    From Osteosarcoma (2022) · cites this paper as [104]

  • Bone and soft-tissue sarcomas remain difficult to monitor across diagnosis, treatment, and follow-up.

    “remain difficult to monitor across diagnosis, treatment, and follow-up [ 1 , 2 ]”
  • Bone and soft-tissue sarcomas are rare, heterogeneous mesenchymal malignancies.

    “Bone and soft-tissue sarcomas are rare, heterogeneous mesenchymal malignancies”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56(7):1515-1521.
  2. Brierley JD, Gospodarowicz MK, Wittekind C, eds. TNM Classification of Malignant Tumours. 8th ed. Oxford: John Wiley & Sons; 2016.
  3. Grimer RJ, Bielack S, Flege S, et al. Periosteal osteosarcomaea Eu- ropean review of outcome. Eur J Cancer. 2005;41(18):2806-2811.

Cited by

Sorted by citations

Authors
Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., de Álava, E., Dei Tos, A. P., Garcia del Muro, X., Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Gaspar, N., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Gronchi, A., Haas, R., Hassan, A. B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R. L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krákorová, D. A., Le Cesne, A., Le Grange, F., Legius, E., Leithner, A., López Pousa, A., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A. B., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M. A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A. A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, M. A. J., van der Graaf, W. T. A., van Houdt, W. J., Frebourg, T., Ladenstein, R., Casali, P. G., & Stacchiotti, S.
Affiliations
  • University College London Hospitals NHS Foundation Trust (GB)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Instituto Português de Oncologia Francisco Gentil (PT)
  • Homi Bhabha National Institute (IN)
  • University of Duisburg-Essen (DE)
  • Instituto Nazionale Tumori Regina Elena (IT)
  • Olgahospital (DE)
  • Centre Léon Bérard (FR)
  • Institut Gustave Roussy (FR)
  • Institut Curie (FR)
  • Oslo University Hospital (NO)
  • Royal Manchester Children's Hospital (GB)
  • Vienna General Hospital (AT)
  • Centro di Riferimento Oncologico (IT)
  • Skåne University Hospital (SE)
  • Ospedale Regina Margherita (IT)
  • Université Paris-Saclay (FR)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
  • Leiden University Medical Center (NL)
  • Candiolo Cancer Institute (IT)
  • University of Milan (IT)
  • University of Oxford (GB)
  • Hospital Universitario Fundación Jiménez Díaz (ES)
  • University of Mannheim (DE)
  • University of Helsinki (FI)
  • Institute of Cancer Research (GB)
  • Université Libre de Bruxelles (BE)
  • University Medical Center Groningen (NL)
  • St Anna Children's Hospital (AT)
  • National Cancer Center Hospital (JP)
  • Masaryk Memorial Cancer Institute (CZ)
  • KU Leuven (BE)
  • University of Graz (AT)
  • Tel Aviv Sourasky Medical Center (IL)
  • Centre Hospitalier Universitaire Vaudois (CH)
  • Birmingham Women’s and Children’s NHS Foundation Trust (GB)
  • Istituto Ortopedico Rizzoli (IT)
  • IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • Helios Hospital Berlin-Buch (DE)
  • The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
  • Aarhus University Hospital (DK)
  • Azienda Ospedale - Università Padova (IT)
  • Universitair Ziekenhuis Leuven (BE)
  • Erasmus MC Cancer Institute (NL)
  • Royal Marsden Hospital (GB)
  • Institute of Oncology Ljubljana (SI)
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2021-12
Volume
32
Issue
12
Pages
1520-1536
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3197355167
Cited by
513
References
99
Citations by year
2026: 137 · 2025: 118 · 2024: 111 · 2023: 88 · 2022: 54 · 2021: 4
FWCI
41.84
Type
journal article
Language
en
Open access
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • IRIS (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Lirias (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • SERVAL (Université de Lausanne) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
European Society for Medical Oncology
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Keywords
primary bone sarcoma, osteosarcoma, Ewing sarcoma, conventional chondrosarcoma, pediatric bone tumors, diagnosis, treatment, follow-up
MeSH terms
Bone Neoplasms, Follow-Up Studies, Humans, Sarcoma, Osteosarcoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review